US FDA declines to approve Replimune's drug for advanced skin cancer
10/04/2026 16:22
April 10 (Reuters) - The U.S. Food and Drug Administration on Friday declined to approve Replimune's REPL.O drug for advanced skin cancer, the regulator said. (Reporting by Padmanabhan Ananthan & Sruthi Narasimha Chari in Bengaluru) ((Padmanabhan.Ananthan@thomsonreuters.com))
Recent news on Bristol-Myers Squibb Co
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Bristol Myers Squibb Announces Dividend
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC